Market Snapshot
S&P Futures
3,819
Dow Futures
30,822
Nasdaq Futures
11,785
Aadi Bioscience Inc (AADI) stock rallied over 0.15% intraday to trade at $13.45 a share on NASDAQ. The stock opened with a gain of 6.41% at $13.5 and touched an intraday high of $14.1, rising 0.15% against the last close of $13.43. The stock went to a low of $13.305 during the session.
Prev. Close
Market Cap
Day Low
Open
Number of Shares
Day High
P/E ratio
EPS (TTM)
Cash Flow per Share
Free Float in %
Book Value
Volume
Date | Open | High | Low | Close | Volume |
---|---|---|---|---|---|
2022-07-06 | $13.5 | $14.1 | $13.305 | $13.45 | 114,426 |
2022-07-05 | $12.64 | $13.46 | $12.64 | $13.43 | 153,400 |
2022-07-01 | $12.36 | $12.85 | $12.26 | $12.77 | 59,000 |
2022-06-30 | $12.62 | $12.97 | $12.18 | $12.32 | 129,500 |
2022-06-29 | $11.83 | $13.14 | $11.78 | $12.98 | 285,700 |
2022-06-28 | $12.08 | $12.33 | $11.72 | $11.92 | 479,900 |
2022-06-27 | $12.29 | $12.615 | $11.96 | $12.1 | 165,200 |
2022-06-24 | $13.3 | $13.5 | $12.13 | $12.16 | 1,642,700 |
2022-06-23 | $12.65 | $13.32 | $12.65 | $13.25 | 227,700 |
2022-06-22 | $12.5 | $12.755 | $12.25 | $12.5 | 176,100 |
Employees-
Beta1.58
Sales or Revenue1.12 Million
5Y Sales Change-
Fiscal Year Ends2021-12-30
SectorHealth Care
IndustryPharmaceuticals
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Aadi Bioscience Inc (NASDAQ: AADI) stock price is $13.45 as of the last check on Wednesday, July 6. During the trading session, AADI stock reached the peak price of $14.1 while $13.305 was the lowest point it dropped to.
The NASDAQ listed AADI is part of Pharmaceuticals industry that operates in the broader Health Care sector. Aadi Bioscience, Inc. , a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes.
Dr. Neil P. Desai Ph.D.
Founder, CEO, Pres, Sec. & Director
Ms. Marcy Graham
SVP of Investor Relations & Corp. Communications
Dr. Neil P. Desai Ph.D.
Founder, Pres, CEO, Sec. & Director
Mr. Scott M. Giacobello CPA
CFO & Treasurer
AADI stock traded closed the last session at $13.45, which is $0.02 or 0.15% lower than its previous close of $13.43. AADI's current trading price is 22.27% lower than its 52-week high of $49.80 where as its distance from 52-week low of 11.00% is -72.99%.
Number of AADI employees currently stands at -. AADI operates from 17383 Sunset Boulevard, Suite A250, Pacific Palisades, CA 90272, United States.
Official Webiste of $AADI is: https://aadibio.com
AADI could be contacted at AADI operates from 17383 Sunset Boulevard, Suite A250, Pacific Palisades, CA 90272, United States, or at phone #424 473 8055 and can also be accessed through its website.
AADI stock volume for the day was 114,798 shares while in the previous session number of AADI shares traded was 114,426 . The average number of AADI shares traded daily for last 3 months was 148.46 Thousands.
The percentage change in AADI stock occurred in the recent session was 0.15% while the dollar amount for the price change in AADI stock was $0.02.
In the recent session, the day high for AADI stock was $14.1 while the low for AADI stock touched on the day was $13.305.
The market value of AADI currently stands at 271.69 Million with its latest stock price at $13.45 and 20.91 Million of its shares outstanding.